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Stem cells are the core of tissue repair and regeneration, and a promising cell source for novel therapies. In recent years, re-
search into stem cell therapies has been particularly exciting in China. The remarkable advancements in basic stem cell re-
search and clinically effective trials have led to fresh insights into regenerative medicine, such as treatments for sweat gland 
injury after burns, diabetes, and liver injury. High hopes have inspired numerous experimental and clinical trials. At the same 
time, government investment and policy support of research continues to increase markedly. However, numerous challenges 
must be overcome before novel stem cell therapies can achieve meaningful clinical outcomes. 
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Regenerative medicine is a rapidly rising multidisciplinary 
field that aims to restore, maintain or enhance the function 
of tissues and organs. The continuing expansion of medical 
research and rapid increase of new medical technologies are 
believed to play important roles in the emerging field of 
regenerative medicine. With China’s rapid economic 
growth and aging population, the healthcare burden of de-
generative diseases, tumors, tissue and organ defects, and 
other age-related diseases has increased gradually. However, 
current therapeutic strategies either are limited by donor 
availability and immunological barriers or pertain to only a 
minor range of conditions. Moreover, such conditions are 
unlikely to be completely cured by current traditional treat-
ments or drugs, and need restoration of tissue function 
through novel therapeutic approaches. For many incurable 
diseases and disorders of the aging population, innovative 
applications of tissue engineering and novel cell therapies 
derived from pluripotent and tissue-restricted stem cells 
represent major frontiers for the future [1]. 
1  Frontline innovations 
Over the last 20 years, scientists and clinicians around the 
world have carried out numerous animal experiments and 
clinical trials of stem cells and achieved remarkable results. 
In 2005, the United States (US) Food and Drug Administra-
tion (FDA) approved an orphan drug product consisting of 
human stem cells (Prochymal, Osiris Pharmaceuticals, USA) 
for graft-versus-host disease in acute rejection treatment. 
Provacel™, the second product of this company Osiris 
Therapeutics Inc. for heart repair, has been evaluated in a 
phase I clinical study. Recently, its third product, Chondro-
gen™, has received FDA approval to begin a clinical phase 
I/II study to repair tissue damage and prevent knee arthritis. 
In 2011, the South Korean Food and Drug Administration 
approved the sale of Hearticellgram-AMI that was devel-
oped by FCB-Pharmicell Inc. for myocardial infarction 
treatment. It is also the first therapeutic stem cell drug ap-
proved for marketing by a government. This first indicates 
that therapeutic stem cells have been recognized as a drug 
for regenerative medicine, which may prompt a new era in 
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stem cell development. 
Stem cell therapy in China ranks at the forefront in the 
world. Because of policy support, China has made consid-
erable progress in basic research of stem cells and attracted 
the most patients for stem cell treatment worldwide. Since 
2002, for rapid and effective development, the Chinese 
government has provided abundant research funding, such 
as that from the National Basic Research Program of China, 
National High Technology Research and Development Pro-
gram of China, and National Natural Science Foundation of 
China (NSFC), to support related research on stem cells. 
Hence, many scientists and clinicians have benefited from 
this funding and accomplished certain achievements [2]. 
Figure1 summarizes the approved projects and funding 
from the NSFC for stem cell-based research and trials, and 
the related articles published in Science Citation Index 
journals from 2008 to 2012. These achievements involved 
preclinical studies of stem cells and tissue engineering 
products for coronary heart diseases, diabetes, liver failure, 
sweat gland injury after burns, and other serious diseases, 
which establish a solid foundation for clinical application 
and industrialization of future products [3–8]. However, the 
therapeutic market for stem cell applications is not mature 
enough in China, resulting in a lack of large-scale mar-
ket-oriented stem cell-based products. The Chinese gov-
ernment has recognized the seriousness of this problem. 
Therefore, the former Health Ministry halted all stem cell 
therapy in early 2012. Although therapeutic stem cells are 
controversial, the market is still growing rapidly. The rea-
sons are as follows: (i) high expectations and unmet medical 
need, (ii) lack of strict supervision awareness, and (iii) rela-
tively easy-to-master technology. In 2013, the Health and 
Family Planning Commission published “Regulations on 
cell clinical trials base construction” and another three 
documents, hoping to effectively take the monitoring re- 
sponsibility. Recently, “management approach on stem cell 
clinical trials (on trial)” and “management approach on stem 
cell clinical trial research base (on trial)” have been pro-
posed by the Stem Cell Expert Committee of China, and the 
relevant terms should drive rapid development of stem  
cell-based therapies in China. 
2  Different types of stem cells for research and 
clinical trials 
Before filing an investigational new stem cell for applica-
tion, the applicant should be able to address the following 
questions: Does the donor pose a risk of transmitting infec-
tious or genetic diseases? Does the cell or tissue processing 
pose a risk of contamination or damage? What are the types 
of cells, and what are the purity and potency of the cells in 
the final product? Will the product be safe and effective in 
vivo [9]? Initially, one of the foremost considerations must 
be the cell types. By 2013, a search of www.clinicaltrials. 
gov, a US government-sponsored website, with the term 
‘‘stem cells’’ lists almost 2000 trials. The relative ratio of 
open trials approved for different stem cell types is listed on 
clinicaltrials.gov, which indicates a wide range of stem cell 
types are being applied to clinical trials (Figure 2). 
2.1  Hematopoietic stem cells (HSCs) 
HSCs are multipotent cells that reside in the bone marrow, 
peripheral blood, placenta, and other tissues that sustain the 
hematopoietic system. Accumulated literature has con-
firmed that HSCs are able to reconstitute the hematopoietic 
system in disease-related bone marrow failure and bone 
marrow aplasia. In fact, apart from HSC transplantation, 
essentially all other stem cell treatments remain experi-
mental or preclinical [10]. Currently, the majority of clinical 
trials aim to build on decades of research and clinical expe-
rience in hematopoietic transplantation. New strategies in-
clude expansion of suboptimal numbers of HSCs within 
umbilical cord blood, correction of gene defects in HSCs 
through viral transgene delivery, and engineering T cells to 
attack malignancies via adoptive immunotherapy [11,12]. 
Despite the relatively poor understanding of the therapeutic 
mechanisms, other stem cells, such as mesenchymal, adi-
pose-derived, and neural stem cells, are being tested innu-
merous animal experiments and clinical trials. 
 
 
Figure 1  Approved projects and funding from the NSFC and related published articles on stem cell-based research and trials from 2008 to 2012. 
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Figure 2  Pie chart of major stem cell types in clinical trials. The relative 
ratios of approved trials for hematopoietic, neural, mesenchymal, embry-
onic and other tissue-derived stem cells as listed on the US National Insti-
tutes of Health website, clinicaltrials.gov. 
2.2  Mesenchymal stem cells (MSCs)  
MSCs are usually derived from bone marrow but can be 
isolated from adipose and other tissues. They are defined by 
their fibroblast-like morphology and capacity for osteogenic, 
chondrogenic, and adipogenic fates in vitro [13]. MSCs 
have also been reported to regenerate functional sweat 
glands, which may help to solve the problem of sweat gland 
depletion in patients surviving extensive deep burns [4]. 
Easy access to large quantities is an advantage of adi-
pose-derived stem cells that are being tested for soft-tissue 
repair and regeneration. Both autologous and allogeneic 
MSCs are being evaluated in vivo to improve healing that 
reflects their in vitro potential to form bone or cartilage for 
use in bone fracture and joint cartilage repair [14]. Although 
such studies appear to indicate strong evidence and sound 
scientific hypotheses, evidence for the robust clinical effi-
cacy of MSCs for orthopedic indications has been chal-
lenging to confirm. To date, no therapy based on MSCs has 
been approved by the FDA. The difficulty in proving thera-
peutic efficacy based on the well-characterized potentials of 
MSCs suggests that our understanding of how even familiar 
stem cells can be used therapeutically in vivo remains poor. 
Furthermore, although MSCs are being tested in a wide 
range of clinical indications, their therapeutic mechanisms 
are not defined completely, and in some cases, the preclini-
cal evidence is highly contentious [15]. At the same time, 
the clinical application of MSCs continues to increase 
markedly. Recently, numerous studies have revealed a vari-
ety of mechanisms including paracrine effects, neoangio-
genesis, and biomechanical alterations because of scarring 
[16–18]. Moreover, MSCs have been widely tested for their 
capacity to mitigate autoimmunity. MSC-mediated tissue 
regeneration has undergone considerable evolution. Unfor-
tunately, the remarkable advancements in basic stem cell 
research with implications have so far not been translated 
into clinically effective therapies.  
2.3  Umbilical cord blood stem cells (UCBSCs) 
The umbilical cord is a rich source of HSCs that can be eas-
ily extracted and cryopreserved, and used to reconstitute the 
blood system, thus allowing establishment of human leuko-
cyte antigen-typed stem cell banks. However, controversy 
exists concerning whether cord blood can serve as a source 
of MSCs that can differentiate into cells of different con-
nective tissue lineages such as bone, cartilage, and adipose. 
Little success has been reported in the literature regarding 
the isolation of such cells from cord blood [19]. Recently, 
umbilical cord blood has emerged as a viable alternative to 
other sources of HSCs for the treatment of leukemia and 
nonmalignant hematologic conditions [20]. It has also be-
come a common source for experimental interventions in a 
wide variety of nonhematological indications as disparate as 
myocardial infarction, multiple sclerosis, amyotrophic lat-
eral sclerosis, cerebral palsy, traumatic brain injury, stroke, 
and inherited metabolic disorders [21–24]. While UCBSCs 
can mediate therapeutic effects in theory, nonhematological 
indications for UCBSC transplantation have not been wide-
ly accepted in standard practice. Without a deeper under-
standing of their basic therapeutic mechanisms, it is difficult 
to implement therapeutic strategies and clinical investiga-
tions on a large scale. 
2.4  Neural stem cells (NSCs) 
NSCs can be obtained from fetal and adult brain, and have 
been demonstrated to differentiate into neurons, oligoden-
drocytes, and astrocytes in vitro. Considering the wide 
range of neurological conditions that have devastating clin-
ical consequences, there is remarkable interest in the thera-
peutic potential of neural regeneration. However, stroke, 
traumatic brain injury, spinal paralysis, and neurodegenera-
tive diseases are among the most daunting challenges for 
regenerative medicine. There are hundreds of clinical trials 
in academic settings and those performed by several com-
panies to develop novel therapies through intracerebralor 
spinal transplantation of NSCs [25]. StemCells Inc. (Irvine, 
California, USA) has tested NSCs in Batten’s disease (neu-
ronal ceroid lipofuscinosis), and documented safe delivery 
but discontinued the trial because of the inability to accrue 
an adequate number of patients. Their current focus      
is Pelizaeus-Merzbacher disease, a myelin disorder, and 
chronic spinal cord injury. Other companies are testing NSC 
transplantation for stroke (ReNeuron, UK), amyotrophic 
lateral sclerosis (Neuralstem, Inc., USA), and Parkinson’s 
disease (NeuroGeneration, USA). In most cases, the clinical 
implications being tested do not depend on the generation of 
neurons, but on complementation of enzyme deficiencies, 
remyelination, or modulation of endogenous repair through 
neoangiogenesis or neuroprotection. 
2.5  Embryonic stem cells (ESCs) 
In theory, ESCs are pluripotent because they show the ca-
pacity to generate every type of cell and tissue of the body 
[26]. However, there are comparatively few clinical trials of 
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products derived from ESCs. For example, current clinical 
trials involve human ESC-based interventions for retinal 
blindness. The retina is accessible for local cell delivery, 
which can be monitored by direct visualization. In addition, 
the retina may provide a certain degree of immune privilege. 
Despite only one patient in each trial, subretinal injection of 
human ESC-derived retinal pigment epithelial cells has 
been applied to Stargardt’s macular degeneration and 
age-related macular degeneration, which were sponsored by 
Advanced Cell Technologies (Marlborough, USA) [27]. 
Only one of the two patients showed evidence of persistent 
cells but both patients showed some restoration of visual 
perception. Because of the limited numbers of patients in-
volved and the very brief period of follow-up (4 months), it 
is difficult to draw conclusions from these early trials. Nev-
ertheless, the trials are milestones because investigators 
succeeded in clearing considerable regulatory hurdles and 
met very high standards of preclinical cell characterization 
and quality control prior to exposing patients to the risk of 
products derived from ESCs.  
While MSCs, NSCs, and ESC-based products are being 
tested in numerous clinical trials, tissue engineering, as an-
other arm of regenerative medicine, is particularly appealing. 
The potential for therapeutic innovation of stem cell biology 
and tissue engineering represents a solution for the medical 
needs of specific patients as acceptably performed and 
highly innovative and individualized therapies. Taken to-
gether, development of such novel therapies, sound scien-
tific rationale and methods, institutional and practitioner 
accountability, thorough and rigorous informed consent, 
patient follow-up, timely reporting of adverse events, peer 
review of therapeutic claims, and publication in medical 
literature are indispensable and meaningful. 
3  Barriers and challenges 
The maturation of a new therapeutic approach requires 
decades, and stem cell-based therapy is no exception. A 
major problem hindering the development of these new 
therapeutics, in our opinion, is insufficient translation of 
basic research findings to patients. In many settings, the 
clinic and the basic research laboratory are often completely 
different. Basic and clinical scientists, as well as scientists 
working in the biotechnology and pharmaceutical industries, 
need increased awareness of the questions that must be an-
swered before a stem cell-based product can be used clini-
cally. Unlike pharmaceutical products, many stem cell- 
based products may originate from academic laboratories 
where researchers are unfamiliar with the applicable regula-
tions. For clinical efficacy, clinicians have to be involved 
from an early stage of basic stem cell research and not just 
immediately before application to patients [28]. Further-
more, basic scientists should acknowledge the clinical 
problems related to the diagnosis and therapy of diseases. 
The partnership between basic scientists and clinicians must 
function throughout all stages of clinical translation if basic 
research findings are to be efficiently converted to novel 
treatments. Hence, based on our multidisciplinary teams and 
multimodal approaches, we recently established a special-
ized biological treatment ward at our hospital for efficient 
clinical translation. Moreover, successful clinical translation 
of stem cells will depend on not only the right type of cell, 
but also an appropriate site for cell delivery as well as suita-
ble patients [28–30]. 
Other barriers to applying stem cell-based treatments are 
the high costs and uncompetitive business development. For 
effective clinical translation, scientists should perform 
health economic studies at an early stage to estimate the 
potential value of further research in stem cell therapy for 
various disorders to ensure the best use of research invest-
ments. Translation of discoveries in basic stem cell research 
into safe and effective clinical products will be very expen-
sive. The estimated costs of stem cell therapies will be im-
portant for companies and scientific institutions manufac-
turing stem-cell-based products [31]. In the US, the transi-
tion from discovery to therapy usually involves profit enti-
ties. Several companies have made discoveries, obtained 
preclinical proof of principle, and even performed phase I/II 
clinical trials in the stem cell field. Unfortunately, domestic 
companies developing stem cell-based products are rather 
lacking. Even estimating the cost of stem cell therapy by 
health economics modeling is uncommon in China [32]. 
Despite significant research funding provided by the gov-
ernment, it is far from enough. This current situation may 
further delay the development of clinically effective stem 
cell therapies in China. 
The most significant hurdle that remains for stem cell 
therapies is unproven therapies without regulation. Admin-
istering interventions outside of controlled trials threatens 
patients and harms the integrity of public trust in medical 
research [33]. Because of the particular vulnerabilities of 
patients, many governments have established laws to protect 
patients from risk, but some medical practitioners regard the 
regulations as a burden and constraint on their trials [34]. 
Recently, the German government shut down the Xcell 
Clinic when a child died after receiving unproven intracra-
nial injections of cord blood. While most stem cell interven-
tions are documented to have no side effects, safety issues 
still require attention [35]. To advance clinical investigation 
and promotion of medical innovation while protecting pa-
tients and ensuring integrity in regenerative medicine, the 
International Society for Stem Cell Research (ISSCR) as-
sembled an international group of scientists, surgeons, 
genetherapists, bioethicists, patient advocates, and attorneys 
to create ‘‘The ISSCR Guidelines for the Clinical Transla-
tion of Stem Cells’’ [36]. These guidelines articulate princi-
ples and standards as a guide for practitioners and regulato-
ry bodies when considering if, when, or how to allow trials 
of experimental stem cell therapies in patients. The reliabil-
ity of the preclinical evidence for efficacy and safety of 
stem cell-based products and rigorous decisions by those 
who are free of conflicts of interest are essential for consid-
ering the potential risks against the potential benefits before 
launching a clinical trial. 
 Huang S, et al.   Sci China Life Sci   February (2014) Vol.57 No.2 161 
4  Conclusion 
Translation of the basic discoveries of stem cell biology into 
effective and safe therapies will overcome numerous chal-
lenges and technical barriers. Before success, stem cell- 
based regenerative medicine will suffer many setbacks. 
Although the challenges of stem cell application are com-
plex and should not be underestimated, the development of 
novel stem cell-based therapies will benefit greatly from 
experience and failures as well as increasing support. We 
hope that the new field of regenerative medicine can ad-
vance by solving challenges effectively. 
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